Finland-based Valo Therapeutics Oy has appointed Hemanshu Shah as chief business officer, to be based in the US, to help expand the company’s network of potential oncology partners. Dr Shah was most recently head of corporate development at the French biotech Transgene SA and before that, was an executive at Astellas Pharma Inc. He holds a PhD in pharmaceutical sciences from Rutgers University and an MBA from the University of Buffalo, both in the US, and a Bachelor of Pharmacy degree from the University of Mumbai, India
Valo Therapeutics announced the appointment on 16 June 2022
Copyright 2022 Evernow Publishing Ltd